Compare CRESY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | KROS |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | Argentina | United States |
| Employees | 2889 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.2M | 584.9M |
| IPO Year | N/A | 2020 |
| Metric | CRESY | KROS |
|---|---|---|
| Price | $11.79 | $11.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 254.0K | ★ 321.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.14% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.39 | $9.79 |
| 52 Week High | $14.21 | $22.55 |
| Indicator | CRESY | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 50.53 |
| Support Level | $11.12 | $10.47 |
| Resistance Level | $12.25 | $12.43 |
| Average True Range (ATR) | 0.42 | 0.69 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 96.09 | 65.08 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.